Chaperone-rich cell lysates, immune activation and tumor vaccination
/in Dendritic Cells, Hyperthermia, International Publications /von 2005-05-11 / Cancer Immunol. Immunother. 2006 Mar;55(3):329-38Emerging evidence indicates that physiologically relevant thermal stress regulates dendritic cell function
/in Dendritic Cells, Hyperthermia, International Publications /von 2005-04-28 / Cancer Immunol. Immunother. 2006 Mar;55(3):292-8Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity
/in Dendritic Cells, International Publications /von 2005-04-04 / J. Leukoc. Biol. 2005 Aug;78(2):319-24Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma
/in Dendritic Cells, Glioblastoma, International Publications /von 2005-04-01 / J. Neurooncol. 2005 Apr;72(2):107-13Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2005-03-11 / Am. J. Respir. Crit. Care Med. 2005 May;171(10):1168-77The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC)
/in Dendritic Cells, International Publications, NSCLC /von 2005-03-01 / Lung Cancer 2005 Mar;47(3):337-50Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination
/in Breast Cancer, Dendritic Cells, International Publications /von 2005-02-01 / Scand. J. Immunol. 2005 Feb;61(2):147-56Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy
/in Cervical Cancer, Dendritic Cells, International Publications /von 2005-01-01 / Curr. Pharm. Des. 2005;11(27):3485-500Chemo-immunotherapy of breast cancer using vesiculated alpha-tocopheryl succinate in combination with dendritic cell vaccination
/in Breast Cancer, Dendritic Cells, International Publications /von 2005-01-01 / Nutr Cancer 2005;53(2):177-93
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de